



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 13, 2025

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Outcome of Board Meeting - Unaudited Financial Results for the quarter ended June 30, 2025 held today, August 13, 2025

Ref: Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter ended June 30, 2025, which were approved by the Board of Directors of the Company at their Meeting held today, that commenced at 2.00 p.m. and concluded at 3.45 p.m.

Please also find enclosed herewith the Limited Review Report issued by the Statutory Auditors namely, B S R & Co. LLP in respect of the said Unaudited Financial Results.

The above is for your information and record.

For Pfizer Limited

Prajeet Nair
Director – Corporate Services & Company Secretary

Encl.: A/a

Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

SRM

Limited Review Report (Continued)

Pfizer Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Sreeja Marar

Partner

Mumbai

13 August 2025

Membership No.: 111410

UDIN:25111410BMNYMQ1085



Pfizer Limited
The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Unaudited Financial Results for the Quarter ended 30 June 2025

(₹ in crore except earnings per share)

	Particulars	3 months ended 30/06/2025	3 months ended 31/03/2025	Preceding 3 months ended 30/06/2024	Previous year ended 31/03/2025
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	603.05	591.91	562.86	2,281.35
	(b) Other income	67.17	44.58	41.84	172.25
	Total income	670.22	636.49	604.70	2,453.60
2	Expenses				
	(a) Cost of materials consumed	88.69	70.64	57.74	272.34
	(b) Purchases of stock-in-trade	124.28	139.52	187.59	512.75
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	(1.74)	(7.68)	(44.64)	25.36
	(d) Employee benefits expense	95.82	82.91	91.37	371.33
	(e) Finance costs	3.25	2.69	2.11	8.41
	(f) Depreciation and amortization expense	14.41	16.40	14.60	60.79
	(g) Other expenses	85.98	79.02	93.31	359.34
	Total expenses	410.69	383.50	402.08	1,610.32
3	Profit before tax and exceptional items (1 - 2)	259.53	252.99	202.62	843.28
4	Exceptional items (Refer Note 5)	-	172.81	-	172.81
5	Profit before tax (3 + 4)	259.53	425.80	202.62	1,016.09
6	Tax expense				
	(a) Current tax	67.39	99.06	55.05	264.10
	(b) Deferred tax	0.39	(4.20)	(3.14)	(15.61)
7	Net profit for the year (5 - 6)	191.75	330.94	150.71	767.60
8	Other comprehensive income				
	(a) Items that will not be reclassified subsequently to profit or loss	(1.23)	3.14	(0.72)	0.99
	(b) Income tax related to items that will not be reclassified to profit or loss	0.31	(0.79)	0.18	(0.25)
	Other comprehensive income, net of taxes	(0.92)	2.35	(0.54)	0.74
9	Total comprehensive income for the period / year (7 + 8)	190.83	333.29	150.17	768.34
10	Paid-up equity share capital (Face value per share ₹10)	45.75	45.75	45.75	45.75
11	Other equity				4,171.66
12	Earnings per share - Basic and Diluted (of ₹10/- each) # Computed on the basis of net profit for the year	41.91*	72.34*	32.94*	167.79

Earnings per share - Basic and Diluted before Exceptional items

*Not annualised

CIN: L24231MH1950PLC008311

Email ID: contactus.india@pfizer.com

Website: www.pfizerltd.co.in

✓

NOTES:

1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on August 13, 2025.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The financial results for the quarter ended June 30, 2025 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerltd.co.in
4. Figures for the quarter ended March 31, 2025 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2024 which were subject to a limited review by the statutory auditors.
5. During the quarter ended March 31, 2025, the Company had received requisite approvals from MIDC to assign and assume the Lease of MIDC Land and Sale of Building constructed on such land and has completed the transfer and sale of said assets. Net gain of ₹172.81 crore (net of carrying value of ₹31.75 crore and cost to sell - Premium and other charges ₹59.84 crore, net of recovery) is disclosed as an 'Exceptional items' in the financial results.
6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
7. The Company does not have any subsidiary company or associate company or joint venture company as at June 30, 2025.

For Pfizer Limited



Meenakshi Nevatia
Managing Director

August 13, 2025